AVEO Pharmaceuticals, Inc. (AVEO): Price and Financial Metrics

AVEO Pharmaceuticals, Inc. (AVEO)

Today's Latest Price: $5.08 USD

0.16 (-3.05%)

Updated Dec 3 12:39pm

Add AVEO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

AVEO Stock Summary

  • AVEO's price/sales ratio is 25.6; that's higher than the P/S ratio of 92.74% of US stocks.
  • Revenue growth over the past 12 months for Aveo Pharmaceuticals Inc comes in at -80.02%, a number that bests just 1.84% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AVEO comes in at -28.97% -- higher than that of only 11.46% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Aveo Pharmaceuticals Inc, a group of peers worth examining would be ONCT, SNSS, APVO, QUIK, and AKBA.
  • AVEO's SEC filings can be seen here. And to visit Aveo Pharmaceuticals Inc's official web site, go to www.aveooncology.com.

AVEO Stock Price Chart Interactive Chart >

Price chart for AVEO

AVEO Price/Volume Stats

Current price $5.08 52-week high $10.71
Prev. close $5.24 52-week low $2.23
Day low $5.03 Volume 189,824
Day high $5.28 Avg. volume 483,501
50-day MA $5.85 Dividend yield N/A
200-day MA $5.42 Market Cap 146.35M

AVEO Pharmaceuticals, Inc. (AVEO) Company Bio

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for patients with cancer and related diseases. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

AVEO Latest News Stream

Event/Time News Detail
Loading, please wait...

AVEO Latest Social Stream

Loading social stream, please wait...

View Full AVEO Social Stream

Latest AVEO News From Around the Web

Below are the latest news stories about Aveo Pharmaceuticals Inc that investors may wish to consider to help them evaluate AVEO as an investment opportunity.

AVEO Pharmaceuticals: Time For Redemption

AVEO Pharmaceuticals, Inc. (AVEO) is at a major crossroads at this time with the New Drug Application (NDA) for tivozanib accepted finally by the U.S. FDA in June 2020, after multiple trials and two CRLs over eight years, with the company shifting goal posts from being first-line to second-line to...

Avisol Capital Partners on Seeking Alpha | September 29, 2020

The Daily Biotech Pulse: Moderna Expands Into Switzerland, Tiziana To Spin Off Testing Unit, Metacrine IPO

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Avidity Biosciences Inc (NASDAQ: RNA ) Beigene Ltd (NASDAQ: BGNE ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Guardant Health Inc (NASDAQ: GH ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunovant Inc (NASDAQ: IMVT ) InVitae Corp (NYSE: NVTA ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Marinus Pharmaceuticals Inc (NASDAQ: MRNS ) ( announced a positive late-stage readout for ganaxolone) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA ) Myokardia Inc (NASDAQ: MYOK ) Novocure Ltd (NASDAQ: NVCR ) Outset Medical Inc (NASDAQ: OM ) (more than...

Benzinga | September 16, 2020

Aveo announces final results from late-stage study of tivozanib in kidney cancer

AVEO Oncology (AVEO) announces that final results from the Phase 3 TIVO-3 study comparing Fotivda (tivozanib) to Bayer's (BAYRY) Nexavar (sorafenib) in renal cell carcinoma ((RCC)) patients in third- and fourth-line settings were just published in the journal European Urology.Consistent with its announcement in May, the trial met the primary...

Seeking Alpha | September 15, 2020

Aveo wins dismissal of investor lawsuit over cancer drug candidate

Massachusetts-based drug company Aveo Pharmaceuticals has won dismissal of a proposed class action lawsuit accusing it of misleading investors about the prospects of a cancer drug it is developing.

Reuters | July 24, 2020

New Strong Sell Stocks for July 1st

Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today

Yahoo | July 1, 2020

Read More 'AVEO' Stories Here

AVEO Price Returns

1-mo -10.56%
3-mo 7.40%
6-mo -30.98%
1-year -32.27%
3-year -82.05%
5-year -55.83%
YTD -18.63%
2019 -60.98%
2018 -42.65%
2017 416.67%
2016 -57.14%
2015 50.00%

Continue Researching AVEO

Here are a few links from around the web to help you further your research on Aveo Pharmaceuticals Inc's stock as an investment opportunity:

Aveo Pharmaceuticals Inc (AVEO) Stock Price | Nasdaq
Aveo Pharmaceuticals Inc (AVEO) Stock Quote, History and News - Yahoo Finance
Aveo Pharmaceuticals Inc (AVEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7973 seconds.